Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Pediatr Blood Cancer
; 62(6): 1078-80, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-25556556
We report a 14 year-old female with Giant Cell Tumor of Bone, successfully treated with denosumab, who developed critical hypercalcemia after completion of therapy. Five months after her last denosumab treatment, serum calcium rose to 16.5 mg/dL (normal 8.7-10.8 mg/dL), nearly double her prior level of 8.4 mg/dL while receiving denosumab. She required emergent intervention to treat her hypercalcemia, which was attributed to rebound osteoclast activity and osteopetrotic bone. Denosumab is widely used in adults and increasingly in pediatric oncology populations and our experience demonstrates the need for close monitoring for electrolyte derangements following discontinuation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ósseas
/
Tumor de Células Gigantes do Osso
/
Ligante RANK
/
Anticorpos Monoclonais Humanizados
/
Hipercalcemia
Limite:
Adolescent
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article